These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 36505475)

  • 41. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
    Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
    Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
    Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
    Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination.
    Geanes ES; LeMaster C; Fraley ER; Khanal S; McLennan R; Grundberg E; Selvarangan R; Bradley T
    Sci Rep; 2022 Apr; 12(1):6496. PubMed ID: 35444221
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
    Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M
    Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4
    Tye EXC; Jinks E; Haigh TA; Kaul B; Patel P; Parry HM; Newby ML; Crispin M; Kaur N; Moss P; Drennan SJ; Taylor GS; Long HM
    Nat Immunol; 2022 Dec; 23(12):1726-1734. PubMed ID: 36456735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel mAb broadly neutralizes SARS-CoV-2 VOCs in vitro and in vivo, including the Omicron variants.
    Kan Q; Lin X; Li T; Ke X; Jian X; Hou L; Zhang W; Wan Z; Xie Q; Shao H; Ye L; Ye J; Qin A; Zou Z; Chen Q
    J Med Virol; 2023 Mar; 95(3):e28657. PubMed ID: 36912367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
    Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques.
    He WT; Yuan M; Callaghan S; Musharrafieh R; Song G; Silva M; Beutler N; Lee WH; Yong P; Torres JL; Melo M; Zhou P; Zhao F; Zhu X; Peng L; Huang D; Anzanello F; Ricketts J; Parren M; Garcia E; Ferguson M; Rinaldi W; Rawlings SA; Nemazee D; Smith DM; Briney B; Safonova Y; Rogers TF; Dan JM; Zhang Z; Weiskopf D; Sette A; Crotty S; Irvine DJ; Ward AB; Wilson IA; Burton DR; Andrabi R
    Sci Transl Med; 2022 Aug; 14(657):eabl9605. PubMed ID: 35947674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.
    Garcia-Valtanen P; Hope CM; Masavuli MG; Yeow AEL; Balachandran H; Mekonnen ZA; Al-Delfi Z; Abayasingam A; Agapiou D; Stella AO; Aggarwal A; Bouras G; Gummow J; Ferguson C; O'Connor S; McCartney EM; Lynn DJ; Maddern G; Gowans EJ; Reddi BAJ; Shaw D; Kok-Lim C; Beard MR; Weiskopf D; Sette A; Turville SG; Bull RA; Barry SC; Grubor-Bauk B
    Cell Rep Med; 2022 Jun; 3(6):100651. PubMed ID: 35654046
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern.
    Svetlova J; Gustin D; Manuvera V; Shirokov D; Shokina V; Prusakov K; Aldarov K; Kharlampieva D; Matyushkina D; Bespyatykh J; Varizhuk A; Lazarev V; Vedekhina T
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs.
    Thura M; Sng JXE; Ang KH; Li J; Gupta A; Hong JM; Hong CW; Zeng Q
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34519332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine.
    Qin J; Jeon JH; Xu J; Langston LK; Marasini R; Mou S; Montoya B; Melo-Silva CR; Jeon HJ; Zhu T; Sigal LJ; Xu R; Zhu H
    Front Immunol; 2023; 14():1126392. PubMed ID: 37033973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.
    Martínez-Flores D; Zepeda-Cervantes J; Cruz-Reséndiz A; Aguirre-Sampieri S; Sampieri A; Vaca L
    Front Immunol; 2021; 12():701501. PubMed ID: 34322129
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern.
    Al-Fattah Yahaya AA; Khalid K; Lim HX; Poh CL
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a promiscuous conserved CTL epitope within the SARS-CoV-2 spike protein.
    Jiang S; Wu S; Zhao G; He Y; Guo X; Zhang Z; Hou J; Ding Y; Cheng A; Wang B
    Emerg Microbes Infect; 2022 Dec; 11(1):730-740. PubMed ID: 35171086
    [No Abstract]   [Full Text] [Related]  

  • 59. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.
    Wang Z; Zhao Z; Cui T; Huang M; Liu S; Su X; Li G; Song T; Li W; Zhong N; Xu M; Yang X; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):829-840. PubMed ID: 35230230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population.
    Bednarski E; Del Rio Estrada PM; DaSilva J; Boukadida C; Zhang F; Luna-Villalobos YA; Rodríguez-Rangel X; Pitén-Isidro E; Luna-García E; Díaz Rivera D; López-Sánchez DM; Tapia-Trejo D; Soto-Nava M; Astorga-Castañeda M; Martínez-Moreno JO; Urbina-Granados GS; Jiménez-Jacinto JA; Serna Alvarado FJ; Enriquez-López YE; López-Arellano O; Reyes-Teran G; Bieniasz PD; Avila-Rios S; Hatziioannou T
    mBio; 2022 Aug; 13(4):e0084022. PubMed ID: 35735743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.